Europass Curriculum Vitae Personal information First name/ Surname E-mail Nationality Annalisa Milano annalisa.milano@uniroma1.it Italian Desired employment / Occupational field Work experience Dates From November 2012 to nowadays Occupation or position held PhD student in Experimental And Clinical Research Methodology In Oncology at Department of Medical and Surgical Sciences and Translational Medicine. Research fellow at Department of Clinical and Molecular Medicine part of the project entitled: Studio di fase II randomizzato sull associazione di inibitori di pompa protonica e chemioterapia nel trattamento neoadiuvante delle neoplasie gastriche. Main activities and responsibilities Overall goal of the PhD program is to identify and characterize Breast Cancer and Colorectal cancer stem cells (CSCs) from residual tumor after neoadjuvant chemotherapy (NAC) and to integrate data relevant to the molecular/metabolic/phenotipic analysis of CSCs with the histopathological features of the tumor and the clinical course of the disease. Overall goal of the research grant is recruitment patients, assessment of PFS and OS in the two treatment arms (standard CHT vs CHT + proton pump inhibitors). Name and address of employer University of Rome Sapienza, Medical Oncology Unit, Sant Andrea Hospital, 1035-1039, Grottarossa Street, 00189, Rome, Italy Clinical research and Clinical car Occupation or position held Main activities and responsibilities Dates From April 2012 to October 2012 Awarded of a research fellowship of the Italian Association of Medical Oncology (AIOM) for young oncologists on breast cancer. She carried out a research project concerning the identification of circulating tumor cells in patients with metastatic breast cancer. Name and address of employer University of Rome Sapienza, Medical Oncology Unit, Sant Andrea Hospital, 1035-1039, Grottarossa Street, 00189, Rome, Italy Translational research and Clinical care Occupation or position held Dates From March 2008 to March 2012 Doctor in specialist training in Medical Oncology Page 1/5 - Curriculum vitae of
Main activities and responsibilities Name and address of employer Identification of putative cancer stem cells in multiple myeloma (in vitro studies) Potential applications of Everolimus (RAD001) in controlling the osteoclasts activation in multiple myeloma and breast cancer (in vitro models) University of Bari Aldo Moro, Medical Oncology School. Polyclinic of Bari, 11 Giulio Cesare Place, 70120, Bari, Italy Basic research and Clinical care Education and training Title of qualification awarded Principal subjects/occupational skills covered Dates March 2012 Postgraduate Medical Education in Oncology. Mark: 70/70 and praise Observation and management of patients with a wide variety of neoplastic diseases; acquisition of knowledge on biology of cancer, principles of therapy, and proper conduct and interpretation of translational and clinical research. Faculty of Medicine and Surgery, University of Bari Aldo Moro Dates July 2007 Title of qualification awarded Degree in Medicine and Surgery. Vote: 110/110 Principal subjects/occupational skills covered Undergraduate medical program Faculty of Medicine and Surgery, University of Bari Aldo Moro Dates June 1998 Title of qualification awarded High school Diplome. Vote: 58/60 Scietific High School R.Canudo of Gioia del Colle (BA) Personal skills and competences Mother tongue Italian Other language Self-assessment European level (*) English Understanding: - Listening: good - Reading: great Speaking: - spoken interaction: simple - spoken production: simple Writing: great Social skills and competences Excellent ability to work in a team and organizational; excellent propensity for clinical management of patients, associated with speculation of basic research; large capacity of recruitment in clinical trials and data management. Page 2/5 - Curriculum vitae of
Driving licence Driving License B Pubblications Romiti A, Onesti CE, Roberto M, Barucca V, Tomao S, D'Antonio C, Durante V, Milano A, Falcone R, Di Rocco R, Righini R, Marchetti P. Continuous, low-dose capecitabine for patients with recurrent colorectal cancer. Med Oncol. 2015 Mar;32(3):54. Giacinti S, Bassanelli M, Aschelter AM, Milano A, Roberto M, Marchetti P. Resistance to abiraterone in Castration-Resistant Prostate Cancer: a review of the literature. Anticancer Res. 2014; 34(11): 6265-6269. D Antonio C, Milano A, Righini R, Onesti CE, Bassanelli M, Falcone R, Paris I, Lauro S and MarchettI P. Pharmacogenomics in Lung Cancer Chemotherapy: A Review of What the Oncologist Should Know. Anticancer Res. 2014; 34(10): 5241-5250. Romiti A, Raffa S, Di Rocco R, Roberto M, Milano A, Romiti A, Raffa S, Di Rocco R, Roberto M, Milano A, Zullo A, Leone L, Ranieri D, Mazzetta F, Medda E, Sarcina I, Barucca V, D'Antonio C, Durante V, Ferri M, Torrisi MR, Marchetti Pet. Circulating Tumor Cells Count Predicts Survival in Colorectal Cancer Patients. J Gastrointestin Liver Dis. 2014; 23(3): 279-84. Cives M, Milano A, Dammacco F, Silvestris F: Lenalidomide in multiple myeloma: current experimental and clinical data. European Journal of Haematology (2012), 88 (4): 279-291. Ciavarella S, Milano A, Savonarola A, Brunetti O, Dammacco F, Silvestris F: Cancer stem cells in Multiple Myeloma. Chapter 6 of the book Cancer Stem Cells- The Cutting Edge, published by InTech (2011), 111-132. (http://www.intechopen.com/articles/show/title/cancerstem-cells-in-multiple-myeloma.) Ciavarella S, Milano A, Dammacco F, Silvestris F: Targeted therapies in cancer. Biodrugs (2010), 24 (2): 77-88. Milano A, Stucci S, Strippoli S, Silvestris F: Le metastasi ossee: aspetti patogenetici e clinici. Biochimica Clinica (2010), vol.34 n 1: 11-18. Page 3/5 - Curriculum vitae of
Conference Abstracts Milano A et al. Epithelial and mesenchymal molecular markers in circulating tumor cells (CTCs) from non small cells lung cancer (NSCLC) patients. i supplementi di TUMORI, a Journal of Experimental and Clinical Oncology Volume 15, Number 1, October 2014. Roberto M, D Antonio C, Romiti A, Milano A et al. Metronomic capecitabine in metastatic colorectal cancer: a phase II trial. i supplementi di TUMORI, a Journal of Experimental and Clinical Oncology Volume 15, Number 1, October 2014. Roberto A, Romiti A, Di Rocco R, Raffa S, Ranieri D, Milano A et al. Can we predict time to tumor progression in early colorectal patients using CTCs count?. Ann Oncol 2013; 24 (suppl4):iv25. Doi:10.1093/annonc/mdt202. POSTER DISCUSSANT al XV Esmo WGI, Barcellona 3-6 Luglio 2013 Milano A et al. Can cardio-vascular toxicity and BMI evaluations predict outcomes in patients treated with chemotherapy plus bevacizumab for metastatic colorectal cancer? i supplementi di TUMORI, a Journal of Experimental and Clinical Oncology Volume 14, Number 1, October 2013;S19. Romiti A, Milano A, et al. Clinical outcomes in patients with colorectal cancer and liver metastases: The times they are a-changin. i supplementi di TUMORI, a Journal of Experimental and Clinical Oncology Volume 14, Number 1, October 2013;S15. D Antonio C, Romiti A, Lombardini A, Durante V, Milano A, et al. MTHFR C677T gene polymorphisms and susceptibility to cardiovascular adverse events in metastatic colorectal cancer treated with chemotherapy plus bevacizumab. i supplementi di TUMORI, a Journal of Experimental and Clinical Oncology Volume 14, Number 1, October 2013;S14. Milano A et al. Are myeloma cells derived from cancer stem cell by a de-differentiation program?. 7 SIICA Congresso Nazionale SIICA Bari, 26-29 Maggio 2010. Convention, Meeting, Courses As Teacher/Speaker Le opzioni terapeutiche nel trattamento del tumore della prostata. Roma, 10 Giugno 2015 Best of the year. Roma, 23 Gennaio 2015 I disturbi elettroliti del paziente neoplastico. Roma, 15 Gennaio 2015 Il carcinoma renale: il trattamento della malattia metastatica; Roma, 18 Novembre 2014. Il tumore dello stomaco. Roma, 13 Novembre 2014. Aiom-Airo-Siuro- Giovani specialisti a confronto: i tumori urologici; Bari, 20 Maggio 2014. Prospettive italiane nel carcinoma renale avanzato; Roma, 21 Marzo 2014. Percorso diagnostico terapeutico del paziente con carcinoma prostatico; Roma, 20 Marzo 2014. Conferenza AIOM di consenso sulle cure simultanee; Roma, 19-20 Settembre 2013. Docenza del Corso di Formazione nell ambito del Progetto Strategico Le Biotecnologie applicabili alla Target Therapy in Oncologia (BIOTECNOTER); Bari 28 Gennaio 2010, 15 Febbraio 2010. Page 4/5 - Curriculum vitae of
Specialization courses IV CORSO NAZIONALE AIOM e SIAPEC-IAP Percorso e metodologia nella diagnostica molecolare in oncologia ; Roma, 26 Marzo 2014 CORSO EDUCAZIONALE MACROREGIONALE AIOM GIOVANI Metodologia della ricerca clinica in oncologia ; Roma, 19, 20 Aprile 2013 XXIX CONFERENZA NAZIONALE DI CITOMETRIA La cellula: ricerca biologica, diagnostica e nuove terapie. Le sfide della citometria. Salerno, 5-8 Ottobre 2011 WORKSHOP Hematopoietic stem cells: saggi clonogenici e controlli di qualità. Roma, 21 Settembre 2010. I authorize the treatment of the personal data transmitted, according to the Italian laws Dlgs 196/2003 and the L. 675/96 Roma, 08/10/2015 Dr. Annalisa Milano Page 5/5 - Curriculum vitae of